Skip to main content

Table 5 Platinum-based neoadjuvant chemotherapy in BRCA-associated breast cancer

From: Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review

Author

n

Setting

Regimen

Efficacy

Byrski et al. 2010 [4]

12

Neoadjuvant

Cisplatin

pCR rate: 83%

Byrski et al. 2014 [5]

107

Neoadjuvant

Cisplatin

pCR rate: 61%

Moiseyenko et al. 2015 [6]

5

Neoadjuvant

Cisplatin

pCR rate: 60%

Sharma et al. 2016 [13]

30

Neoadjuvant

Carboplatin+Docetaxel

pCR rate: 59%

Back to article page

Hereditary Cancer in Clinical Practice

ISSN: 1897-4287